Search
Dexamethasone Treatment Options
A collection of 1456 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
289 - 300 of 1456
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients with Metastatic Appendiceal Adenocarcinoma
Recruiting
To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Active Not Recruiting
This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Chicago, Chicago, Illinois +2 locations
Conditions: Multiple Myeloma
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Active Not Recruiting
* This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study.
* This Treatment Extension study has the purpose to provide continued access to isatuximab. Adult participants with multiple myeloma who have enrolled on an isatuximab parental study for which study objectives are completed will be eligible to be enrolled in this Treatment E... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Washington University- Site Number : 8400001, Saint Louis, Missouri +36 locations
Conditions: Plasma Cell Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
Active Not Recruiting
This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Multiple Myeloma
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency
Recruiting
This is a single-arm, open-label phase II study with a safety lead-in phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Multiple Myeloma
Pre vs Post Block in Total Knee Arthroplasty (TKA)
Completed
The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee arthroplasty can be observed with the substitution of a post operative adductor canal block for a preoperative adductor canal block in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: University of Miami, Miami, Florida
Conditions: Knee Osteoarthritis, Arthroplasty Complications, Postoperative Pain
Venetoclax Plus Inotuzumab for B-ALL
Recruiting
This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL)
The names of the study drugs involved in this study are:
* Venetoclax
* Inotuzumab ozogamicin
* Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
Ixazomib + Pomalidomide + Dexamethasone In MM
Active Not Recruiting
This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma, Multiple Myeloma in Relapse
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Recruiting
This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2025
Locations: Retina Associates of Florida, LLC, Tampa, Florida
Conditions: Diabetic Macular Edema
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruiting
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), fol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona +56 locations
Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
Completed
Primary Objective:
To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory multiple myeloma (MM).
Secondary Objectives:
* To evaluate the Overall Response Rate (ORR) as per International Myeloma Working Group (IMWG) criteria in each arm.
* To compare the Overall Survival (OS) betwee... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: BRCR Medical Center Inc. Site Number : 8400002, Plantation, Florida +110 locations
Conditions: Plasma Cell Myeloma
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Active Not Recruiting
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM).
FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +9 locations
Conditions: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
289 - 300 of 1456